Welcome to our dedicated page for LHDX news (Ticker: LHDX), a resource for investors and traders seeking the latest updates and insights on LHDX stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect LHDX's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of LHDX's position in the market.
Lucira Health has announced interim results from a pilot study showing a 98% accuracy rate for its combined Chlamydia and Gonorrhea assays in its at-home testing platform. The study, involving over 150 female participants, builds on previous research indicating 94% sensitivity and 99% specificity. The development is funded by grants from the National Institutes of Health. With an expected rise in STI screening, Lucira aims to improve accessibility to rapid testing, addressing the growing STI burden, which sees more than 2.2 million cases annually in the U.S. alone.
Lucira Health, a medical technology company, announced its participation in the LifeSci Partners HealthTech Symposium on September 21, 2022, at 10:30 AM ET. The event will showcase Lucira's innovative infectious disease test kits and its digital health platform aimed at connecting patients with providers. The company has made lab-quality diagnostics more accessible with its PCR-quality test results, expanding its offerings beyond COVID-19 to include tests for respiratory infections, women's health, and STIs. A live webcast will be available on Lucira's website.
Lucira Health, a medical technology company, will participate in the Gilmartin Group Emerging Growth Company Showcase on August 31, 2022. The virtual presentation is scheduled for 4:30 pm ET and will be accessible via the company's website. Lucira focuses on developing innovative infectious disease tests aimed at providing lab-quality diagnostics.
Lucira Health (LHDX) reported impressive financial results for Q2 2022, achieving $26.1 million in net revenue, up 110% year-over-year. The company received regulatory approvals in Canada and New Zealand for its COVID-19 & Flu tests, indicating strong market expansion potential. Gross profit surged to $8.0 million with a gross margin of 31%, recovering from losses in 2021. However, operating expenses rose significantly to $29.4 million, leading to a net loss of $21.7 million. Despite challenges, Lucira anticipates improved cash flow and continued product development for respiratory diseases.
Lucira Health has received Health Canada's authorization for its COVID-19 & Flu Test, marking it as the first at-home test for both viruses. This 99% accurate rapid molecular test provides results in under 30 minutes from one shallow nasal swab. Prioritized distribution aims to meet consumer demand ahead of the fall and winter seasons. The company conducted extensive clinical studies with 677 tested samples, showcasing its test's reliability compared to traditional PCR tests. The test is currently available for online ordering in Canada.
Lucira Health, a medical technology company specializing in innovative infectious disease test kits, will report its second quarter 2022 financial results on August 15, 2022. Management will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results and provide updates. Lucira's testing platform includes consumer-friendly kits designed for reliable, on-the-spot molecular test results within 30 minutes, significantly enhancing accessibility to COVID-19 testing. For more details, visit their website.
Lucira Health, a medical technology company, announced the grant of 1,051,405 restricted stock units (RSUs) to new employees on July 27, 2022. This grant, approved by its Board of Directors, serves as an inducement to support new employment, in line with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years, with an initial 25% vesting after a year, followed by quarterly vesting, contingent on continued employee service. Lucira specializes in innovative infectious disease testing technologies, including rapid COVID-19 testing kits.
Lucira Health reported strong first-quarter results for 2022, achieving net revenue of $90.5 million, reflecting a 19-fold increase compared to the same period in 2021. The company noted a net income of $13.1 million, marking its first positive quarter. Operating expenses rose to $26.1 million due to increased headcount and services aimed at commercial activities. The company withdrew its 2022 revenue guidance of $450 million due to uncertainties surrounding COVID-19 infection rates. Lucira also received CE Marks for its COVID-19 and Flu tests, enhancing its market presence.
Lucira Health has submitted a request to the U.S. FDA for emergency use authorization (EUA) for its inaugural at-home COVID-19 & Flu test. This test is designed to differentiate between COVID-19 and influenza, delivering results within 30 minutes. The product is essential as SARS-CoV-2 and flu are expected to co-circulate in the upcoming fall and winter. Lucira's testing platform boasts sensitivity and specificity comparable to lab-based PCR tests. The test has already received CE Mark, indicating its readiness for international markets.
Lucira Health, Inc. (Nasdaq: LHDX) announced that its COVID-19 & Flu and COVID-19 molecular tests have received CE Mark approval for professional use, facilitating their sale across the European Union. These tests are Nucleic Acid Amplification Tests (NAAT) that yield results in 30 minutes with comparable sensitivity and specificity to traditional PCR assays. The COVID-19 & Flu test can independently diagnose COVID-19, Flu A, and Flu B from one nasal swab. Lucira expects to launch these tests in the EU in Q3 2022, ahead of the flu season.
FAQ
What is the market cap of LHDX (LHDX)?
